BioMark Diagnostics Inc.
BUX
CNSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 14.70% | 51.22% | -14.05% | 12.91% | 33.98% |
| Total Depreciation and Amortization | -2.89% | -75.27% | 142.11% | 47.42% | 72.04% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 49.09% | -24.14% | 17.76% | -84.45% | -93.41% |
| Change in Net Operating Assets | -231.13% | 98.22% | -95.53% | -146.06% | -12.40% |
| Cash from Operations | 11.14% | 72.66% | -6.64% | -265.14% | 11.90% |
| Capital Expenditure | -- | 64,185.71% | -- | -- | 22.22% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 117.25% | -- | -- | -- | -- |
| Cash from Investing | 117.23% | 105,971.43% | -- | -- | -75,566.67% |
| Total Debt Issued | 0.00% | -723.96% | 567.09% | 0.00% | 0.00% |
| Total Debt Repaid | 0.63% | -54.14% | -25.33% | -26.72% | -21.62% |
| Issuance of Common Stock | -- | -99.23% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 137.17% | -128.26% | 130.42% | -341.14% | -132.06% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 104.75% | -94.33% | -535.58% | 573.15% | -14,548.21% |